Diagnostic Sensitivity of NLR and PLR in Early Diagnosis of Gastric Cancer

Abstract

The neutrophil-lymphocyte ratio (NLR) and the platelet-lymphocyte ratio (PLR) are markers of systemic inflammation. However, there is little evidence of the value of inflammation in the early diagnosis of gastric cancer (GC). A total of 2,606 patients diagnosed with GC in the past three years and 3,219 healthy controls over the same period were included in this study. Peripheral blood samples were obtained to analyze the NLR, PLR, carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9). The optimal cutoff levels for the NLR and PLR were defined by receiver operating characteristic (ROC) curve analysis (NLR=2.258, PLR=147.368). The value of different biomarkers for diagnosing GC was compared by the area under the curve (AUC). The NLR and PLR showed diagnostic sensitivity in GC (AUC=0.715, AUC=0.707). Using the Bonferroni correction, the NLR and PLR were superior to CEA and CA19-9 in the diagnosis of GC (P<0.0001). The systemic inflammatory markers were significantly higher in the early stage of GC than tumor markers. After grouping patients and healthy controls by gender, we found that the diagnostic significance of combined NLR and PLR for GC was greater in male patients than in female patients (P<0.0001). The diagnostic value of the NLR and PLR in GC is higher than that of the traditional tumor markers CEA and CA19-9. Systemic markers of inflammation are more valuable in male than female patients.

Differential Expression Analysis Revealing CLCA1 to Be a Prognostic and Diagnostic Biomarker for Colorectal Cancer

“…In some cases, the levels of biomarkers do not change. In other diseases, the levels of biomarkers can change (4,5). In addition, some patients do not undergo colonoscopy because of the discomfort of this procedure (6).…”

Albumina e índice neutrófilo-linfocito como predictores de estadío tumoral en pacientes con cáncer gástrico

“…No se encontró asociación entre el sexo y el INL elevado, albúmina sérica baja y estadío tumoral avanzado. Si bien el sexo femenino se ha vinculado con un efecto protector antitumoral al interaccionar con los receptores de estrógenos, esto no ha sido demostrado definitivamente en metaanálisis y estudios aleatorizados (35) .…”

“…Después de años de investigación, las pruebas de CTC se aprobaron para uso clínico. Sin embargo, la rareza, la heterogeneidad y el alto costo de las pruebas de CTC plantean desafíos para usarlas como biomarcadores (35)(36)(37) . Esto ha llevado a los investigadores a considerar seriamente el fenómeno de que las células cancerosas ingresan a la sangre periférica en la etapa inicial del cáncer, pero la metástasis temprana es rara (38,39) .…”

Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet–Lymphocyte Ratio in Patients Receiving XELOX

“…Pathological immunity evaluation may provide reliable information on tumor prognosis (9,10). For early diagnosis of GC, Fang et al (11) demonstrated that neutrophillymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were significantly better than traditional tumor markers. Lee et al (12) found that patients with NLR ≥3 had worse survival after postoperative FOLFOX chemotherapy.…”

“…For early diagnosis of GC, Fang et al. ( 11 ) demonstrated that neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) were significantly better than traditional tumor markers. Lee et al.…”